

infection in Mexico, 1980. *Am J Epidemiol* 1983;117:335-43.

Address for correspondence: Jayanton Patumanond, Department of Community Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; fax: 66+53+945476; email: jpatuman@med.cmu.ac.th

Antimicrobial Drug-resistant *Salmonella* Typhimurium (Reply to Helms)

In Reply to Helms: In the article by Helms et al., Helms concludes that infections with *Salmonella* Typhimurium strains resistant to ampicillin, chloramphenicol, streptomycin, sulfonamide, and tetracycline (hereafter referred to as penta-resistant) were associated with higher death rates than infections with non-penta-resistant *S. Typhimurium*. Helms also concluded that infections with quinolone-resistant (nalidixine-resistant) *S. Typhimurium* were associated with higher death rates than quinolone-susceptible *S. Typhimurium* (1).

Table 2 in Helms' article provides information that enables close scrutiny of this conclusion and comparison of the excess mortality associated with penta-resistant, quinolone-susceptible *S. Typhimurium* with the excess mortality of non-penta-resist-

ant *S. Typhimurium* (1). In this letter, the Table is based on the original table. However, two additional comparisons have been added: the p values, which are not based on the data but are approximations based on the parameters in the table.

The conclusion is that only quinolone resistance is associated with excess mortality compared with nonresistant isolates. Penta-resistant, quinolone-susceptible *S. Typhimurium* has a risk ratio of 2.9 (1.1 to 7.9) compared to the ratio of non-penta-resistant isolates 2.1 (1.5 to 2.9). When these figures are compared, the approximate p value is 0.55, which, of course, is far from being significant. Thus, on the basis of the article by Helms, penta resistance may not pose a greater threat to human health than non-penta resistance. However, the measured effect of penta resistance is achieved by the inclusion of quinolone-resistant *S. Typhimurium* in the group.

Jan Dahl*

*Danish Bacon and Meat Council, Copenhagen, Denmark

Reference

1. Helms M, Vastrup P, Gerner-Smidt P, Mølbak K. Excess mortality associated with antimicrobial drug-resistant *Salmonella* Typhimurium. *Emerg Infect Dis* 2002;8:490-5.

Address for correspondence: Jan Dahl, Danish Bacon and Meat Council, Axeltovej 3, 1609 Copenhagen V, Denmark; fax: 4533145756; email: JD@danskesslagterier.dk

Antimicrobial Drug-resistant *Salmonella* Typhimurium (Reply to Dahl)

In Reply to Dahl: The emergence and spread of multidrug-resistant *Salmonella enterica* serovar Typhimurium DT104 (MDR DT104) contributed to an international increase in antimicrobial drug resistance in *S. Typhimurium* in the late 1990s (1,2). This type of *Salmonella* is usually resistant to five drugs: ampicillin, chloramphenicol, streptomycin, sulfonamides, and tetracycline (R-type ACSSuT) and easily acquires resistance to other drugs, including quinolones, trimethoprim, and aminoglycosides (1,3-5). To determine death rates after infection with MDR DT104 or closely related strains, we identified patients who were infected with strains at least resistant to ACSSuT (6). Analysis limited to strains that were only R-type ACSSuT would have given a misleading result since MDR DT104 often, as mentioned, develops additional resistance to other classes of antimicrobial drugs in addition to the ACSSuT-complex. This fact needs to be taken into account in any attempt to quantify the overall public health impact of MDR DT104 and related strains.

We found, in our matched cohort study (6), that 283 patients infected with strains resistant to at least ACSSuT were 4.8 times more likely to die than the general Danish population, compared with 2.3 for 953 patients infected with pansusceptible strains. This difference in death rates occurred mainly because 40 of the 283 strains had R-type ACSSuTNx (i.e., additional resistance to nalidixic acid), and infection with this strain in particular is associated with a high death rate (relative mortality 13.1). As Dahl suggests, infection with R-type ACSSuT (Nx susceptible) was not

Table. Table showing additional comparisons (1)^a

	Resistant		Susceptible		p value
	Deaths/cases	RR ^b (95% CI)	Deaths/cases	RR ^b (95% CI)	
Penta with and without quinolone	12/283	4.8 (2.2 to 10.5)	47/1,764	2.1 (1.5 to 2.9)	0.06
Penta with quinolone	5/40	13.1 (3.3 to 51.9)	47/1,764	2.1 (1.5 to 2.9) ^c	0.01 ^d
Penta without quinolone	7/243	2.9 (1.1 to 7.9)	47/1764	2.1 (1.5 to 2.9) ^c	0.55 ^d

^aRR, relative risk; CI, confidence interval.

^bAdjusted for coexisting conditions.

^cCompared to the non-penta group.

^dApproximations based on the parameters from the table.

associated with excess mortality in the 243 patients included in the analysis, and the measured effect of ACSSuT was achieved by the inclusion of the nalidixic acid-resistant strains in this group. However, all deaths associated with nalidixic acid-resistant strains occurred in the 40 patients with R-type ACSSuTNx (being DT104s), whereas none of the 43 patients infected with non-ACSSuT strains resistant to nalidixic acid died. This finding may be related to small numbers in these subanalyses. However, because 25 of the patients with R-type ACSSuTNx were part of an outbreak, they may have had an average higher exposure dose, which may have contributed to some deaths (3). In addition, an interaction between different resistance traits in *Salmonella* may exist, which may lead to more deaths and disease, or DT104 may be somewhat more virulent than most other *S. Typhimurium* subtypes.

The database that we used for our analysis was updated in May 2002. We have now identified 13 deaths in 342 patients infected with strains resistant to ACSSuT (but Nx susceptible), which corresponds to a relative mortality rate of 4.18 (95% confidence interval [CI] 2.18 to 8.02) compared with a matched sample of the general population. Of 1,432 patients infected with pansusceptible strains, 43 patients died (relative mortality rate 2.64; 95% CI 1.88 to 3.70). In other words, the mortality rate in patients infected with strains resistant to ACSSuT (Nx susceptible) was 1.6 times higher than in patients with pansusceptible strains (p value for homogeneity 0.22). These estimates were not adjusted for coexisting conditions as were the estimates in the paper (6).

We agree with Dahl that particular problems are associated with quinolone resistance in zoonotic salmonellae and that fluoroquinolones may have reduced efficacy to treat patients infected with *Salmonella* strains that are nalidixic acid

(quinolone) resistant (7). We therefore encourage initiatives to preserve the efficacy of fluoroquinolones, including a limitation of their use in agriculture. Whether infection with *S. Typhimurium* R-type ACSSuT, with no additional resistance, is associated with higher disease or death rates than pansusceptible *S. Typhimurium* remains unclear. Although the difference was not significant (p=0.22), our recent estimates suggest that the death rate is approximately 60% higher in patients infected with such strains. This view is corroborated by recent studies from the United States, which suggest that *S. Typhimurium* R-type ACSSuT is associated with an increased risk for blood stream infection (8) and that resistance in nontyphoid *Salmonella* is associated with an increased risk for admission to hospital (9).

**Morten Helms,* Pernille Vastrup,*
and Kåre Mølbak***

*Statens Serum Institut, Copenhagen, Denmark

References

1. Threlfall EJ, Frost JA, Ward LR, Rowe B. Increasing spectrum of resistance in multiresistant *Salmonella* Typhimurium. *Lancet* 1996;347:1053-4.
2. Glynn MK, Bopp C, Dewitt W, Dabney P, Mokhtar M, Angulo FJ. Emergence of multidrug-resistant *Salmonella enterica* serotype Typhimurium DT104 infections in the United States. *N Engl J Med* 1998;338:1333-8.
3. Mølbak K, Baggesen DL, Aarestrup FM, Ebbesen JM, Engberg J, Frydendahl K, et al. An outbreak of multidrug-resistant, quinolone-resistant *Salmonella enterica* serotype Typhimurium DT 104. *N Engl J Med* 1999;341:1420-5.
4. Baggesen DL, Sandvang D, Aarestrup FM. Characterization of *Salmonella enterica* serovar Typhimurium DT104 isolated from Denmark and comparison with isolates from Europe and the United States. *J Clin Microbiol* 2000;38:1581-6.
5. Walker RA, Lawson AJ, Lindsay EA, Ward LR, Wright PA, Bolton FJ, et al. Decreased susceptibility to ciprofloxacin in outbreak-associated multiresistant *Salmonella* Typhimurium DT104. *Vet Rec* 2000;147:395-6.
6. Helms M, Vastrup P, Gerner-Smith P, Mølbak K. Excess mortality associated with antimicrobial drug-resistant *Salmonella typhimurium*. *Emerg Infect Dis* 2002;8:490-5.
7. Aarestrup FM, Wiuff C, Mølbak K, Threlfall EJ. Is it time to change the break points for fluoroquinolones for *Salmonella*? *Antimicrob Agents Chemother* 2003;47:827-9.
8. Mølbak K, Varma J, Rossiter S, Lay J, Joyce K, Stamey K, et al. Antimicrobial resistance in *Salmonella* serotype Typhimurium, R-type ACSSuT, is associated with bacteremia; NARMS, 1996-2000. Proceedings of the International Conference of Emerging Infectious Diseases, 2002 Mar 24-27, Atlanta, Georgia, USA. Available from: URL: <http://www.cdc.gov/iceid/>
9. Varma JK, Mølbak K, Rossiter S, Hawkins MA, Jones TF, Mauvais SH, et al. Antimicrobial resistance in *Salmonella* is associated with increased hospitalization; NARMS 1996-2000. Proceedings of the International Conference of Emerging Infectious Diseases, 2002 Mar 24-27, Atlanta, Georgia, USA. Available from: URL: <http://www.cdc.gov/iceid/>

Address for correspondence: Kåre Mølbak, Department of Epidemiology, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark; fax: 45 3268 3874; email: krm@ssi.dk

Serogroup A *Neisseria meningitidis* Outside Meningitis Belt in Southwest Cameroon

To the Editor: Epidemic meningitis associated with serogroup A *Neisseria meningitidis* is a devastating disease in the absence of vaccination (1). Without treatment, the case-fatality rate is high, approaching 100%. In Africa, such epidemics occur regularly (1) within a well-limited geographic zone, the so-called